Modified human growth hormone

• US 8,143,216 B2
• Filed: 10/25/2007
• Issued: 03/27/2012
• Est. Priority Date: 12/22/2004
• Status: Expired due to Fees

• Current Assignee: Ambrx, Inc. (Johnson & Johnson)
• Original Assignee: Ambrx, Inc. (Johnson & Johnson)
• Inventors: Sim, Bee-Cheng, LITZINGER, David C., Cho, Ho Sung, Daniel, Thomas O., DiMarchi, Richard D., HAYS, Anna-Maria A., Wilson, Troy E.
• Primary Examiner(s): Gamett, Daniel C
• Application Number:
  US11/924,101
• Publication Number:
  US 20080102125A1
• Time in Patent Office: 1,615 Days
• Field of Search: None
• US Class Current: 514/5.1
• CPC Class Codes: A61K 38/27 Growth hormone [GH], i.e. somatotropin
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/26 Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/06 of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
• CPC Class Codes: A61P 5/10 of the posterior pituitary hormones, e.g. oxytocin, ADH
• CPC Class Codes: C07K 14/61 Growth hormone [GH], i.e. somatotropin
• CPC Class Codes: C08G 65/33396 having oxygen in addition to nitrogen

Abstract

Modified growth hormone polypeptide and uses thereof are provided.

Claims

1. A method of increasing percent body weight by administering a human growth hormone (hGH) composition, wherein said hGH is linked to at least one water-soluble polymer by an oxime bond and wherein the hGH comprises a non-naturally encoded amino acid wherein the non-naturally encoded amino acid has the structure:

2. The method of claim 1 wherein the non-naturally encoded amino acid comprises a ketone.

3. The method of claim 2 wherein the non-naturally encoded amino acid is para-acetylphenylalanine.

4. A method of increasing percent body weight by administering a human growth hormone (hGH) composition twice in a fourteen day interval, wherein the amount of hGH composition administered over a 14-day interval has a ≧

50% dose-sparing effect when compared to the amount of somatotropin administered over a 14-day interval required to affect an equal or better increase in percent body weight, and wherein said hGH is linked to at least one water-soluble polymer by an oxime bond and wherein the oxime bond is formed between a non-naturally encoded amino acid and a water-soluble polymer.